ALX Oncology (NASDAQ:ALXO) Receives Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of ALX Oncology (NASDAQ:ALXO) in a research report released on Wednesday morning,Benzinga reports.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of ALX Oncology in a research report on Wednesday. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, ALX Oncology has an average rating of “Moderate Buy” and a consensus price target of $8.50.

ALX Oncology Stock Performance

NASDAQ:ALXO opened at $1.62 on Wednesday. ALX Oncology has a twelve month low of $1.19 and a twelve month high of $17.83. The firm has a market capitalization of $85.44 million, a price-to-earnings ratio of -0.54 and a beta of 1.04. The company has a current ratio of 4.82, a quick ratio of 4.82 and a debt-to-equity ratio of 0.07. The firm’s fifty day simple moving average is $1.49 and its 200 day simple moving average is $3.32.

Insider Activity at ALX Oncology

In other ALX Oncology news, Director Rekha Hemrajani purchased 30,000 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The shares were acquired at an average price of $1.55 per share, for a total transaction of $46,500.00. Following the completion of the purchase, the director now owns 33,000 shares in the company, valued at $51,150. The trade was a 1,000.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 33.40% of the company’s stock.

Institutional Investors Weigh In On ALX Oncology

A number of hedge funds have recently bought and sold shares of ALXO. Barclays PLC raised its position in shares of ALX Oncology by 243.6% in the 3rd quarter. Barclays PLC now owns 59,502 shares of the company’s stock valued at $107,000 after purchasing an additional 42,185 shares in the last quarter. XTX Topco Ltd acquired a new stake in ALX Oncology in the third quarter valued at $578,000. Wellington Management Group LLP raised its holdings in ALX Oncology by 15.2% in the third quarter. Wellington Management Group LLP now owns 167,831 shares of the company’s stock valued at $305,000 after acquiring an additional 22,114 shares in the last quarter. Verition Fund Management LLC boosted its stake in ALX Oncology by 308.4% during the 3rd quarter. Verition Fund Management LLC now owns 133,025 shares of the company’s stock valued at $242,000 after acquiring an additional 100,454 shares during the last quarter. Finally, Walleye Capital LLC grew its holdings in ALX Oncology by 110.3% during the 3rd quarter. Walleye Capital LLC now owns 230,875 shares of the company’s stock worth $420,000 after acquiring an additional 121,113 shares in the last quarter. Institutional investors and hedge funds own 97.97% of the company’s stock.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.